A61P 5 - Drugs for disorders of the endocrine system

Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
12/2002
12/11/2002	CN1384835A Tricycle inhibitors of poly(ADP-ribose) polymerases
12/11/2002	CN1384830A Novel spiroheterocyclic compoundsus reversible inhibitors of cysteine proteases
12/11/2002	CN1384814A Phenoxy carboxylic acid compounds and compositions for delivering active agents
12/11/2002	CN1384757A Method for down-regulating GDF-8 activity
12/11/2002	CN1384755A Novel exendin agonist formulations and methods administration thereof
12/11/2002	CN1384748A Mesoprogestins (progesterone receptor modulators) as component of female contraceptives
12/11/2002	CN1384733A Dry powder compositions having improved dispersivity
12/10/2002	US6492520 Substituted pyrido-or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
12/10/2002	US6492424 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
12/10/2002	US6492409 Such as 5-(1-(3-aminopropyl)-3-indolyl)-1-(3-indolyl)-1,3-dihydroimidazol-2-one; protein kinase c inhibitors; high solubility; reduced color; treating inflammatory and/or immunological disorders
12/10/2002	US6492406 Pharmaceutically active compounds
12/10/2002	US6492403 Methods of treating C1s-mediated diseases and conditions and compositions thereof
12/10/2002	US6492362 Compounds and compositions as cathepsin S inhibitors
12/10/2002	US6492358 For treatment of sexual disorders, male erectile dysfunction
12/05/2002	WO2002097060A2 Carbohydrate-associated proteins
12/05/2002	WO2002097044A2 Alternative splice forms of proteins as basis for multiple therapeutic modalities
12/05/2002	WO2002097030A2 Peptides derived from neural thread proteins and their medical use
12/05/2002	WO2002096927A2 Ribozyme based treatment of female reproductive diseases
12/05/2002	WO2002096911A1 Novel heteroaryl-diazabicyclo-alkanes as cns-modulators
12/05/2002	WO2002096895A1 Oxazol/ thiazol-derivatives activators of the hppar-alpha receptor
12/05/2002	WO2002096892A1 Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
12/05/2002	WO2002096883A1 Tricyclic compounds useful as angiotensin ii agonists
12/05/2002	WO2002096863A1 New phenylalkyloxy-phenyl derivatives
12/05/2002	WO2002096453A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin
12/05/2002	WO2002096410A1 Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
12/05/2002	WO2002096402A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a biguanide drug
12/05/2002	WO2002096396A1 Fine inorganic particles having drug included therein, method for preparation thereof and pharmaceutical preparation comprising fine inorganic particles having drug included therein
12/05/2002	WO2002096358A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002	WO2002070557A3 Nuclear hormone receptor ligand binding domain
12/05/2002	WO2002053110A3 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body
12/05/2002	WO2002013862A3 Method and composition for altering a b cell mediated pathology
12/05/2002	WO2001093840A2 Ligands of integrin receptors
12/05/2002	US20020183524 Preparations and use of an Ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
12/05/2002	US20020183384 Administering sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt for therapy of disease or a disorder responsive to inhibition of nuclear factor- kappa B (NF- kappa B)
12/05/2002	US20020183377 Use of melatonin for treating androgenetic and diffuse alopecia
12/05/2002	US20020183375 For therapy of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms
12/05/2002	US20020183367 2,1-Oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
12/05/2002	US20020183346 Tricyclic androgen receptor modulator compounds and methods
12/05/2002	US20020183319 For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer
12/05/2002	US20020183314 For therapy of acne, male- pattern baldness, sexual dysfunction, impotence, wasting diseases, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia, and hormone-dependent cancers
12/05/2002	US20020183311 Novel hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
12/05/2002	US20020183296 Applying a hydroalcoholic gel containing testosterone to skin of the male subject in an amount effective to treat the hypogonadism
12/05/2002	US20020183291 Use of an aromatase inhibitor selected from exemestane, anastrozole, letrozole and fadrozole in the preparation of a medicament for use in treating gynecomastia in a patient undergoing treatment with antiandrogen
12/05/2002	US20020182681 Peptide for use in treatment of cancer, parkinson's and metabolic disorders
12/05/2002	US20020182655 Method for identifying ligands for G protein-coupled receptors
12/05/2002	DE10118282A1 Haftkleber auf Basis von Ethylen-Vinylacetat-Copolymeren und Klebharzen, für medizinische Verwendungszwecke Pressure-sensitive adhesives based on ethylene-vinyl acetate copolymers and tackifier resins, for medical uses
12/05/2002	CA2449160A1 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002	CA2448645A1 New phenylalkyloxy-phenyl derivatives
12/05/2002	CA2448643A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a biguanide drug
12/05/2002	CA2448637A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin
12/05/2002	CA2448348A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
12/05/2002	CA2448320A1 Ribozyme based treatment of female reproductive diseases
12/05/2002	CA2448205A1 Oxazol/thiazol-derivatives activators of the hppar-alpha receptor
12/05/2002	CA2448148A1 Carbohydrate-associated proteins
12/05/2002	CA2448109A1 Alternative splice forms of proteins as basis for multiple therapeutic modalities
12/05/2002	CA2411549A1 Ligands of integrin receptors
12/04/2002	EP1262190A1 Rfrp-containing prolactin secretion regulatory agent
12/04/2002	EP1262189A1 Leptin-resistance ameliorating agents
12/04/2002	EP1261700A2 Cis acting regulatory nucleic acid sequences in the parathyroid hormone 3'-untranslated region
12/04/2002	EP1261638A2 Human fgf-23 gene and gene expression products
12/04/2002	EP1261635A1 Human polynucleotides, polypeptides, and antibodies
12/04/2002	EP1261624A1 Trh-like peptide derivatives as inhibitors of the trh-degrading ectoenzyme
12/04/2002	EP1261622A2 Purified lh
12/04/2002	EP1261363A2 METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS
12/04/2002	EP1261361A1 Oral, nasal and pulmonary dosage formualtions of copolymer 1
12/04/2002	EP1261330A2 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and in lower animals
12/04/2002	EP1261320A2 Micellar pharmaceutical compositions for buccal and pulmonary application
12/04/2002	CN1382440A Method and medicine case for treating depression or preventing degeneration of cognitive function
12/03/2002	US6489476 Fructose-1,6-bisphosphatase enzyme inhibitors are useful in the treatment of diabetes and other conditions associated with elevated blood glucose or excess glycogen storage.
12/03/2002	US6488960 Corticosteroid formulation
12/03/2002	CA2116120C Peptides having growth hormone releasing activity
12/03/2002	CA2073856C Glp-1 analogs useful for diabetes treatment
11/2002
11/28/2002	WO2002095011A2 Inactivation of genes of the mep pathway
11/28/2002	WO2002095007A2 Conjugates activated by cell surface proteases and therapeutic uses thereof
11/28/2002	WO2002094826A1 Tri-and tetraaza-acenaphthylen derivatives as crf receptor antagonists
11/28/2002	WO2002094825A1 Novel spiropiperidine derivative
11/28/2002	WO2002094788A1 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
11/28/2002	WO2002094780A2 Kinases and phosphatases
11/28/2002	WO2002094754A1 Vitamin d analogues
11/28/2002	WO2002094342A2 Compositions for protein delivery via the pulmonary route
11/28/2002	WO2002094322A2 Combination medicament for treatment of neoplastic diseases containing cyanoguanidine ikk inhibitors and a second anti-neoplastic drug
11/28/2002	WO2002094276A1 Pharmaceutical composition for use in hormone replacement therapy
11/28/2002	WO2002094275A1 Use of estrogen compounds to increase libido in women
11/28/2002	WO2002094268A1 Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
11/28/2002	WO2002094203A2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
11/28/2002	WO2002094192A2 Antibodies against tumor necrosis factor delta (april)
11/28/2002	WO2002080887A3 Timed pulse release composition
11/28/2002	WO2002070563A3 Nuclear hormone receptor ligand binding domain
11/28/2002	WO2002035235A3 Net as regulator of angiogenic expression
11/28/2002	WO2002024924A3 Protein phosphatases
11/28/2002	WO2002009759A3 Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
11/28/2002	WO2002008255A3 Cell cycle proteins and mitosis-associated molecules
11/28/2002	WO2001082897A3 Liposome drug delivery
11/28/2002	WO2001081415A3 Parathyroid hormone and parathyroid hormone-related protein antagonists
11/28/2002	WO2001018021A9 B7-like polynucleotides, polypeptides, and antibodies
11/28/2002	US20020177839 Microprojection array having a beneficial agent containing coating
11/28/2002	US20020177626 Comprises analgesics such as ibuprofen and diphenhydramine; storage stability
11/28/2002	US20020177618 ERK (extracellular signal regulated kinase) inhibitors for treatment of cancer, inflammatory disorders, restenosis, and cardiovascular disease
11/28/2002	US20020177591 Central nervous system (CNS); diazabicyclo compounds such as 1,4-Diaza-bicyclo(3.2.2)nonane-4-carboxylic acid, 4-cyclohexyl-phenyl ester; CNS-penetrant alpha 7 nicotinic receptor agonist
11/28/2002	US20020177545 Compositions and methods for treating gonadotrophin related illnesses

1 ... 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 ... 290